145 related articles for article (PubMed ID: 37865836)
1. Epilepsy in gliomas: recent insights into risk factors and molecular pathways.
Rudà R; Bruno F; Pellerino A
Curr Opin Neurol; 2023 Dec; 36(6):557-563. PubMed ID: 37865836
[TBL] [Abstract][Full Text] [Related]
2. IDH1 and IDH2 mutations in postoperative diffuse glioma-associated epilepsy.
Neal A; Kwan P; O'Brien TJ; Buckland ME; Gonzales M; Morokoff A
Epilepsy Behav; 2018 Jan; 78():30-36. PubMed ID: 29172136
[TBL] [Abstract][Full Text] [Related]
3. An analysis of 170 glioma patients and systematic review to investigate the association between IDH-1 mutations and preoperative glioma-related epilepsy.
Yang Y; Mao Q; Wang X; Liu Y; Mao Y; Zhou Q; Luo J
J Clin Neurosci; 2016 Sep; 31():56-62. PubMed ID: 27406953
[TBL] [Abstract][Full Text] [Related]
4. Mutant IDH1 and seizures in patients with glioma.
Chen H; Judkins J; Thomas C; Wu M; Khoury L; Benjamin CG; Pacione D; Golfinos JG; Kumthekar P; Ghamsari F; Chen L; Lein P; Chetkovich DM; Snuderl M; Horbinski C
Neurology; 2017 May; 88(19):1805-1813. PubMed ID: 28404805
[TBL] [Abstract][Full Text] [Related]
5. Tissue 2-Hydroxyglutarate and Preoperative Seizures in Patients With Diffuse Gliomas.
Ohno M; Hayashi Y; Aikawa H; Hayashi M; Miyakita Y; Takahashi M; Matsushita Y; Yoshida A; Satomi K; Ichimura K; Hamada A; Narita Y
Neurology; 2021 Nov; 97(21):e2114-e2123. PubMed ID: 34610989
[TBL] [Abstract][Full Text] [Related]
6. Isocitrate dehydrogenase mutations in gliomas.
Waitkus MS; Diplas BH; Yan H
Neuro Oncol; 2016 Jan; 18(1):16-26. PubMed ID: 26188014
[TBL] [Abstract][Full Text] [Related]
7. Molecular Classification of Gliomas is Associated with Seizure Control: A Retrospective Analysis.
Easwaran TP; Lancki N; Henriquez M; Vortmeyer AO; Barbaro NM; Scholtens DM; Ahmed AU; Dey M
Neuromolecular Med; 2021 Jun; 23(2):315-326. PubMed ID: 33206320
[TBL] [Abstract][Full Text] [Related]
8. Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress.
Lenting K; Khurshed M; Peeters TH; van den Heuvel CNAM; van Lith SAM; de Bitter T; Hendriks W; Span PN; Molenaar RJ; Botman D; Verrijp K; Heerschap A; Ter Laan M; Kusters B; van Ewijk A; Huynen MA; van Noorden CJF; Leenders WPJ
FASEB J; 2019 Jan; 33(1):557-571. PubMed ID: 30001166
[TBL] [Abstract][Full Text] [Related]
9. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.
Zhang C; Moore LM; Li X; Yung WK; Zhang W
Neuro Oncol; 2013 Sep; 15(9):1114-26. PubMed ID: 23877318
[TBL] [Abstract][Full Text] [Related]
10. High expression of cystine-glutamate antiporter xCT (SLC7A11) is an independent biomarker for epileptic seizures at diagnosis in glioma.
Sørensen MF; Heimisdóttir SB; Sørensen MD; Mellegaard CS; Wohlleben H; Kristensen BW; Beier CP
J Neurooncol; 2018 May; 138(1):49-53. PubMed ID: 29404978
[TBL] [Abstract][Full Text] [Related]
11. IDH-mutated gliomas promote epileptogenesis through d-2-hydroxyglutarate-dependent mTOR hyperactivation.
Mortazavi A; Fayed I; Bachani M; Dowdy T; Jahanipour J; Khan A; Owotade J; Walbridge S; Inati SK; Steiner J; Wu J; Gilbert M; Yang CZ; Larion M; Maric D; Ksendzovsky A; Zaghloul KA
Neuro Oncol; 2022 Sep; 24(9):1423-1435. PubMed ID: 34994387
[TBL] [Abstract][Full Text] [Related]
12. Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma.
Tang F; Pan Z; Wang Y; Lan T; Wang M; Li F; Quan W; Liu Z; Wang Z; Li Z
Neurosci Bull; 2022 Sep; 38(9):1069-1084. PubMed ID: 35670952
[TBL] [Abstract][Full Text] [Related]
13. Seizures and gliomas--towards a single therapeutic approach.
Huberfeld G; Vecht CJ
Nat Rev Neurol; 2016 Apr; 12(4):204-16. PubMed ID: 26965673
[TBL] [Abstract][Full Text] [Related]
14. A juvenile case of epilepsy-associated, isocitrate dehydrogenase wild-type/histone 3 wild-type diffuse glioma with a rare BRAF
Sadashima S; Suzuki SO; Haruyama H; Mukae N; Fujioka Y; Hata N; Mizoguchi M; Ishimatsu K; Hiwatashi A; Iwaki T
Neuropathology; 2020 Dec; 40(6):646-650. PubMed ID: 32996219
[TBL] [Abstract][Full Text] [Related]
15. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.
Malzkorn B; Reifenberger G
Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086
[TBL] [Abstract][Full Text] [Related]
16. IDH1 mutation is associated with seizures and protoplasmic subtype in patients with low-grade gliomas.
Liubinas SV; D'Abaco GM; Moffat BM; Gonzales M; Feleppa F; Nowell CJ; Gorelik A; Drummond KJ; O'Brien TJ; Kaye AH; Morokoff AP
Epilepsia; 2014 Sep; 55(9):1438-43. PubMed ID: 24903073
[TBL] [Abstract][Full Text] [Related]
17. IDH1 mutation is associated with a higher preoperative seizure incidence in low-grade glioma: A systematic review and meta-analysis.
Li Y; Shan X; Wu Z; Wang Y; Ling M; Fan X
Seizure; 2018 Feb; 55():76-82. PubMed ID: 29414139
[TBL] [Abstract][Full Text] [Related]
18. Activation of the mTOR signaling pathway in peritumoral tissues can cause glioma-associated seizures.
Yuan Y; Xiang W; Yanhui L; Ruofei L; Jiewen L; Shu J; Qing M
Neurol Sci; 2017 Jan; 38(1):61-66. PubMed ID: 27646413
[TBL] [Abstract][Full Text] [Related]
19. IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.
Gorovets D; Kannan K; Shen R; Kastenhuber ER; Islamdoust N; Campos C; Pentsova E; Heguy A; Jhanwar SC; Mellinghoff IK; Chan TA; Huse JT
Clin Cancer Res; 2012 May; 18(9):2490-501. PubMed ID: 22415316
[TBL] [Abstract][Full Text] [Related]
20. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]